ASCO GU 2017: Is there a relationship between testosterone levels at the end of short-term androgen deprivation therapy and outcomes in intermediate risk prostate cancer? Prospective data from a phase III trial.

Orlando, Florida USA (UroToday.com) Nabid et al from Canada reported a secondary analysis from NCT00223145 investigating the ability of testosterone level after short term androgen deprivation therapy (ADT) to prognosticate prostate cancer outcomes after combined ADT and radiation. Importantly, the study was carried out in intermediate risk prostate cancer patients. Using castrate level defined as <1.7nmol/L, and castrate patients furthered subclassified as lower (T<0.7) and upper (T between 0.7-1.7), the authors found no difference with regards to biochemical failure, prostate cancer progression or resistance to castration amongst the three groups.

However, small numbers of events were seen for cancer progression and castration resistance. The study may not have been powered to examine the effect of achieving castration on cancer outcomes.

First Author: Abdenour Nabid

at the 2017 Genitourinary Cancers Symposium - February 16 - 18, 2017 – Orlando, Florida USA

Login